AKTX officer Form 3 shows zero beneficial ownership

Rhea-AI Filing Summary

Akari Therapeutics (AKTX) reported an initial beneficial ownership filing on Form 3 for an officer serving as Interim CFO. The filing indicates no securities are beneficially owned, as stated in the remarks. The event date is 10/22/2025, and the form was filed by one reporting person. A Power of Attorney (Exhibit 24) is referenced for the signature authorization.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Farag Kameel D.

(Last) (First) (Middle)

C/O AKARI THERAPEUTICS PLC

401 EAST JACKSON STREET, SUITE 3300

(Street)

TAMPA FL 33602

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/22/2025

3. Issuer Name and Ticker or Trading Symbol
Akari Therapeutics Plc [ AKTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CFO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Ex. 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Abizer Gaslightwala, as Attorney-in-Fact	10/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Akari Therapeutics (AKTX) file?

A Form 3, the initial statement of beneficial ownership of securities by an insider.

Who is the reporting person in this AKTX Form 3?

An officer of the company serving as Interim CFO, filing as one reporting person.

What is disclosed about AKTX insider holdings?

The filing states no securities are beneficially owned.

What is the event date in the AKTX Form 3?

The event date is 10/22/2025.

Is there a Power of Attorney referenced?

Yes. The remarks note Exhibit 24 - Power of Attorney for signature authorization.

What is the relationship of the filer to AKTX?

The filer is an Officer (Interim CFO); not a director or 10% owner per the checkboxes.